Burning Rock Biotech (BNR) Short term Debt (2019 - 2026)

Burning Rock Biotech (BNR) posted quarterly Short term Debt of $29000.0 for Q1 2026, up 2.84% on a QoQ basis from $28198.5 in Q4 2025.

Burning Rock Biotech (BNR) Short term Debt (2019 - 2026) Analysis & Trends

Burning Rock Biotech (BNR) has reported Short term Debt for 5 consecutive years, with $29000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $29000.0 (changed N/A YoY), while the FY2025 annual figure was $29000.0, changed N/A from the prior year.
Short term Debt came in at $29000.0 for Q1 2026 at Burning Rock Biotech, up from $28198.5 in the prior quarter.
The five-year high for Short term Debt was $29000.0 in Q1 2026, with the low at $28000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn
10	Burning Rock Biotech	748.66 Mn	683.48 Mn	11.31 Mn

Download Data